---
id: kdigo-aki-2012
title: "KDIGO Clinical Practice Guideline for Acute Kidney Injury"
short_title: "KDIGO AKI 2012"

organization: Kidney Disease Improving Global Outcomes
collaborators: null
country: null
url: https://kdigo.org/guidelines/acute-kidney-injury/
doi: null
pmid: 22890468
open_access: true

specialty: nephrology
guideline_type: clinical-practice
evidence_system: GRADE
conditions:
  - acute kidney injury
  - AKI
  - renal failure
tags:
  - staging
  - RRT
  - nephrotoxins
  - contrast AKI

publication_date: 2012-03-01
previous_version_date: null
status: current
supersedes: null
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-22
---

## Scope
Evidence-based recommendations for the definition, evaluation, prevention, and treatment of acute kidney injury (AKI).

## Key Recommendations

### Definition and Staging

#### AKI Definition
AKI is defined by any of the following:
- Increase in SCr ≥0.3 mg/dL within 48 hours
- Increase in SCr ≥1.5× baseline within 7 days
- Urine output <0.5 mL/kg/hour for 6 hours

#### Staging
| Stage | Serum Creatinine | Urine Output |
|-------|------------------|--------------|
| 1 | ↑ 1.5-1.9× baseline OR ↑ ≥0.3 mg/dL | <0.5 mL/kg/hr for 6-12 hr |
| 2 | ↑ 2.0-2.9× baseline | <0.5 mL/kg/hr for ≥12 hr |
| 3 | ↑ ≥3× baseline OR ≥4.0 mg/dL OR RRT | <0.3 mL/kg/hr for ≥24 hr OR anuria ≥12 hr |

### Risk Assessment

#### Risk Factors for AKI
| Patient Factors | Exposure Factors |
|-----------------|------------------|
| CKD | Sepsis |
| Advanced age | Critical illness |
| Diabetes | Cardiac surgery |
| Heart failure | Major non-cardiac surgery |
| Liver disease | Nephrotoxic drugs |
| Dehydration | Radiocontrast agents |

### Evaluation

#### Initial Assessment
- Detailed history and medication review
- Volume status assessment
- Urinalysis and urine sediment
- Serum creatinine trend
- Identify reversible causes

#### Diagnostic Workup
| Test | Purpose |
|------|---------|
| Urinalysis | Proteinuria, hematuria, casts |
| Urine electrolytes | FENa, FEUrea |
| Renal ultrasound | Obstruction, kidney size |
| Kidney biopsy | Selected cases (glomerulonephritis, vasculitis) |

### Prevention

#### Fluid Management
- Avoid hypovolemia
- Isotonic crystalloids preferred over colloids
- Avoid hydroxyethyl starch (HES)

#### Contrast-Induced AKI Prevention
| Strategy | Recommendation |
|----------|----------------|
| Volume expansion | IV isotonic saline |
| Contrast volume | Use minimum necessary |
| Iso-osmolar contrast | Preferred in high risk |
| Avoid concurrent nephrotoxins | NSAIDs, aminoglycosides |

#### Medication Considerations
- Review and adjust nephrotoxic medications
- Dose adjust renally cleared drugs
- Avoid NSAIDs in at-risk patients
- Aminoglycosides: Extended-interval dosing

### Management

#### Volume and Hemodynamics
- Restore euvolemia
- Maintain adequate perfusion pressure
- Avoid fluid overload
- Consider vasopressors if needed

#### Glycemic Control
- Target glucose 110-149 mg/dL
- Avoid hypoglycemia
- Avoid hyperglycemia

#### Nutrition
- Achieve total energy intake 20-30 kcal/kg/day
- Protein: 0.8-1.0 g/kg/day (non-catabolic without RRT)
- Protein: 1.0-1.5 g/kg/day (on RRT or hypercatabolic)

### Renal Replacement Therapy

#### Indications for RRT
- Refractory hyperkalemia
- Refractory metabolic acidosis
- Refractory fluid overload
- Uremic symptoms (pericarditis, encephalopathy)
- Severe azotemia

#### Timing of Initiation
- Consider individual patient factors
- Do not delay when indications present
- Earlier RRT has not shown clear benefit

#### Modality Selection
| Modality | Considerations |
|----------|----------------|
| Intermittent HD | Hemodynamically stable patients |
| CRRT | Hemodynamically unstable |
| SLED | Intermediate option |

#### CRRT Prescription
- Dose: 20-25 mL/kg/hour effluent
- Anticoagulation: Regional citrate or systemic heparin

### Discontinuation of RRT
- Improving kidney function
- Adequate urine output
- Decreasing creatinine off dialysis
- Resolution of indications for initiation

### Nephrotoxin Avoidance

#### Common Nephrotoxins
| Drug Class | Considerations |
|------------|----------------|
| NSAIDs | Avoid in AKI/at-risk |
| Aminoglycosides | Once daily dosing, monitor levels |
| Amphotericin B | Use lipid formulations |
| ACE-I/ARB | Hold in acute setting |
| Contrast | Minimize, hydrate |

### Post-AKI Care

#### Follow-Up
- Assess for recovery of kidney function
- Monitor for development of CKD
- Medication reconciliation
- Address modifiable risk factors

#### Long-Term Considerations
- AKI increases risk of CKD
- Increased cardiovascular risk
- Regular monitoring recommended

